COSCIENS Biopharma Inc. (TSX: CSCI)
CSCI trades on the Toronto Stock Exchange in Life Sciences, headquartered in Quebec. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Close · October 14, 2026
C$9.60
-1.03% on the day
Market cap (C$)
C$9.8M
TMX list, September 30, 2026
Market cap (US$)
US$6.9M
Nano cap at 1.4263 C$/US$
1-year return
-70.8%
-62.4% year to date
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for CSCI.TO, last bar 2026-10-14, computed by Sophia Capital.
Profile
| Field | Value |
|---|---|
| Ticker | CSCI on the Toronto Stock Exchange |
| Yahoo symbol | CSCI.TO |
| Sector | Life Sciences |
| Headquarters | Quebec |
| Listed | 1995-12-18 |
| Listing type | TMX leaves listing type blank for long-listed issuers |
| Shares outstanding | 1,061,455 |
| Also listed on | NasdaqCM |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001113423 |
| Website | No company website on record |
Returns
| Window | Return |
|---|---|
| 1 day | -1.0% |
| 1 week | +10.3% |
| 1 month | +25.5% |
| 3 months | +13.1% |
| 6 months | -57.0% |
| Year to date | -62.4% |
| 1 year | -70.8% |
| From 52-week high | -73.2% |
| 52-week range | C$7.05 to C$35.82 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
84 documents in 9 types. Each title links to the document at its source.
Interim financial statements (5)
| Document | Type | Filed |
|---|---|---|
| COSCIENS Biopharma Condensed Interim Consolidated Financial Statements – First Quarter 2026 (Q1) | Interim financial statements (6-K) | 2026-05-12 |
| , 99.2, 99.3, and 99.4 included with this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Period 2025-09-30 | Interim financial statements (6-K) | 2025-11-12 |
| COSCIENS Biopharma Condensed Interim Consolidated Financial Statements – Second Quarter 2025 (Q2) | Interim financial statements (6-K) | 2025-08-14 |
| COSCIENS Biopharma Condensed Interim Consolidated Financial Statements – First Quarter 2025 (Q1) | Interim financial statements (6-K) | 2025-05-13 |
MD&A (4)
| Document | Type | Filed |
|---|---|---|
| COSCIENS Biopharma Management’s Discussion and Analysis of Financial Condition and Results of Operations – First Quarter 2026 (Q1) | MD&A (interim) (6-K) | 2026-05-12 |
| COSCIENS Biopharma Management’s Discussion and Analysis of Financial Condition and Results of Operations – Third Quarter 2025 (Q3) | MD&A (interim) (6-K) | 2025-11-12 |
| COSCIENS Biopharma Management’s Discussion and Analysis of Financial Condition and Results of Operations – Second Quarter 2025 (Q2) | MD&A (interim) (6-K) | 2025-08-14 |
| COSCIENS Biopharma Management’s Discussion and Analysis of Financial Condition and Results of Operations – First Quarter 2025 (Q1) | MD&A (interim) (6-K) | 2025-05-13 |
News release (17)
| Document | Type | Filed |
|---|---|---|
| Press Release, dated July 3, 2026. | News release (6-K) | 2026-07-06 |
| Biopharma Inc. Announces Details of Share Capital Amendment TORONTO, | News release (6-K) | 2026-06-23 |
| Press Release, dated June 18, 2026. | News release (6-K) | 2026-06-18 |
| COSCIENS Biopharma Inc. Reports Q1 2026 Results | News release (6-K) | 2026-05-12 |
Management information circular / proxy (12)
| Document | Type | Filed |
|---|---|---|
| Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, dated May 18, 2026. | Management information circular (6-K) | 2026-05-20 |
| Notice of Annual General and Special Meeting of Shareholders and Management Proxy Circular | Management information circular (6-K) | 2026-04-20 |
| Management Information Circular | Management information circular (6-K) | 2025-06-09 |
| Notice of Annual General and Special Meeting of Shareholders | Notice of meeting (6-K) | 2026-05-08 |
Report of voting results (1)
| Document | Type | Filed |
|---|---|---|
| Report on Voting Results for the Registrant’s Annual General and Special Meeting of Shareholders held June 18, 2026 | Report of voting results (6-K) | 2026-06-18 |
Annual report (4)
| Document | Type | Filed |
|---|---|---|
| 20-F Period 2025-12-31 | Annual report (20-F) (20-F) | 2026-03-25 |
| 20-F form20-f.htm Period 2024-12-31 | Annual report (20-F) (20-F) | 2025-04-09 |
| have reviewed this annual report on Form 20-F of COSCIENS Biopharma Inc.; Period 2025-12-31 | Annual report to shareholders (20-F) | 2026-03-25 |
| have reviewed this annual report on Form 20-F of COSCIENS Biopharma Inc.; Period 2025-12-31 | Annual report to shareholders (20-F) | 2026-03-25 |
Early warning / ownership (3)
| Document | Type | Filed |
|---|---|---|
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2026-04-17 |
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2025-06-11 |
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2024-12-20 |
Certification (10)
| Document | Type | Filed |
|---|---|---|
| Certification of the Principal Financial Officer pursuant to National Instrument 52-109 Period 2026-03-31 | Certification (52-109F2) (6-K) | 2026-05-12 |
| Certification of the Principal Financial Officer pursuant to National Instrument 52-109 Period 2025-09-30 | Certification (52-109F2) (6-K) | 2025-11-12 |
| Certification of the Principal Financial Officer pursuant to National Instrument 52-109 Period 2025-06-30 | Certification (52-109F2) (6-K) | 2025-08-14 |
| Certification of the Principal Financial Officer pursuant to National Instrument 52-109 Period 2025-03-31 | Certification (52-109F2) (6-K) | 2025-05-13 |
Other (28)
| Document | Type | Filed |
|---|---|---|
| EX-8.1 Period 2025-12-31 | Consent (20-F) | 2026-03-25 |
| EX-8.1 ex8-1.htm Period 2024-12-31 | Consent (20-F) | 2025-04-09 |
| Resolution Agreement | Material contract / governance (6-K) | 2025-06-09 |
| EX-97.1 ex97-1.htm Period 2024-12-31 | Material contract / governance (20-F) | 2025-04-09 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
Trading: the last notice, on 2026-09-11, was a resumption.
| Notice | Action | Reason | Notice |
|---|---|---|---|
| 2026-09-11 8:00 AM ET | Resumption | No reason stated | CIRO notice |
| 2026-09-10 3:21 PM ET | Halt | Pending News | CIRO notice |
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2020-03-02 | Option To Acquire, Security To Be Acquired | US$4.5M | US$4.5M | SEC EDGAR |
| 2019-10-01 | Option To Acquire, Security To Be Acquired | US$5.0M | US$5.0M | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| MRVL | Marvel Biosciences Corp. | TSXV | C$9.8M | -26.7% | -51.1% |
| AVNT | Avant Brands Inc. | TSX | C$10.0M | -8.6% | -39.8% |
| ASG | Aurora Spine Corporation | TSXV | C$10.8M | -17.2% | -58.6% |
| RKV | Rakovina Therapeutics Inc. | TSXV | C$10.9M | -10.0% | -19.6% |
| CHS | Comprehensive Healthcare Systems Inc. | TSXV | C$12.0M | -16.5% | -46.8% |
The app has the price chart, every filing, private raises and the full peer set for CSCI.
Open in the app